Position in GYRE
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$166,515
-$9,602 QoQ
Shares Held
25,268
0.0% QoQ
Ownership
0.023%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#16
of 60 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 97%
Shared 3%
None 0%
Common Shares in GYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026DIMENSIONAL FUND ADVISORS LP holds $6,105,781,867 across 230 Biotechnology names. GYRE ranks #194 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,168,956 | $580,655,511 | |
| 2 | JAZZ |
Jazz Pharmaceuticals plc
|
1,713,592 | $412,924,262 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
559,687 | $348,987,230 | |
| 4 | INCY |
Incyte Corp
|
2,280,803 | $258,551,825 | |
| 5 | EXEL |
Exelixis, Inc.
|
4,426,620 | $240,852,392 | |
| 6 | BMRN |
Biomarin Pharmaceutical Inc
|
4,075,714 | $233,212,353 | |
| 7 | ROIV |
Roivant Sciences Ltd.
|
5,230,417 | $185,104,455 | |
| 8 | KRYS |
Krystal Biotech, Inc.
|
476,038 | $176,929,041 |
All Filings in GYRE
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $166,515 | 25,268 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $176,117 | 25,268 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $76,975 | 10,903 | Shares | Sole | 2026-02-12 | |
| No filing history on record for this holder in this stock. | ||||||